Brazil HIV prevention progress

In late July 2026, Brazil showcased a dual focus on cutting‑edge HIV research and domestic prevention policy. At the 26th International AIDS Conference in Rio, scientists reported two additional cases of HIV remission achieved via CCR5‑Δ32 stem‑cell transplants, raising the global tally to 13, and Brazil’s Ministry of Health announced multiple agreements to develop new prophylactic drugs, including the oral candidate Alimatravir and the injectable cabotegravir, while negotiations for lenacapavir stalled over price.

A few days later, researchers presented the first successful germline‑targeting HIV vaccine in rhesus macaques, demonstrating the induction of broadly neutralising antibodies. Brazil’s health minister reiterated the push to widen prevention options by formally requesting that the long‑acting injectable PrEP, already approved by ANVISA, be added to the public SUS system. The vaccine’s promise was framed as a complement to these expanding PrEP tools, underscoring Brazil’s broader strategy to combine innovative biomedical advances with public‑sector rollout.

Overall, the snapshots trace Brazil’s trajectory from celebrating breakthrough remission cases and drug‑development partnerships to seeking regulatory inclusion of injectable PrEP and highlighting emerging vaccine research as part of its effort to curb HIV transmission.